Galvus (vildagliptin) is “not inferior to” Avandia (rosiglitazone) in Treating Type 2 Diabetes

| Mar 17, 2007

A 24-week study compared the effectiveness and safety of Galvus (vildagliptin), a DPP-4 inhibitor, with Avandia (rosiglitazone), a thiazolidinedione, in a double-blind, randomized, controlled, multi-center study. Both drugs had similar effects on A1c’s: Galvus reduced A1c by 1.1 %, and Avandia reduced A1c by 1. 3%. Most notably, patients did not gain weight with Galvus, but gained an average of 3.4 pounds with Avandia.

Galvus, made by Novartis, is in the same class as sitagliptin (Januvia), another DPP-4 inhibitor. Unlike Januvia, Galvus has not been approved by the FDA. FDA approval was expected by November 2006, but then the FDA asked for more data about studies linking Galvus to skin lesions in monkeys. In late February 2007, the FDA asked for a clinical study in patients with kidney impairment. It now looks as if Galvus will not be approved by the FDA for a year or more.

Sources: Diabetes Care
Associated Press

Click Here To View Or Post Comments

Categories: A1c Test, Diabetes, Diabetes, Type 2 Issues, Type 2 Medications

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.